Fight back with Felycin®-CA1
For cats diagnosed with subclinical hypertrophic cardiomyopathy (HCM), the only option has been to watch and wait. But now there’s Felycin®-CA1 (sirolimus delayed-release tablets), the first and only disease-modifying drug conditionally approved by the FDA to effectively manage HCM.
Finally, there’s a way to manage feline HCM
The first and only FDA conditionally-approved drug for HCM
Medication that modifies the disease
Can help improve quality of life for cats with HCM
Simple once-weekly dosing for cats
How Felycin-CA1 works
Subclinical hypertrophic cardiomyopathy (HCM) causes the muscular wall in a cat’s left ventricle to thicken. This decreases the heart’s ability to efficiently pump oxygenated blood to the cat’s body. Felycin-CA1 can help prevent and delay this process.
Studies show cats receiving Felycin-CA1 experienced improvement in heart wall measurements compared to cats that didn’t receive treatment.1
Give Your Clinic the Power to Change Outcomes
Felycin-CA1 helps you intervene earlier in cats with subclinical HCM—because every proactive step can mean a longer, healthier life.
More Time Together Starts with Early Action
Ask your veterinarian about Felycin-CA1. Early detection and treatment can help your cat live the life you imagined.
References
1 Kaplan JL, Rivas VN, Walker AL, et al. Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial. JAVMA 2023;261(11):1628-1637.